In late April 2026, the Department of Justice under Acting Attorney General Todd Blanche issued a final DEA order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing federal protections and tax relief via Section 280E exemption for qualifying businesses. Broader rescheduling of botanical marijuana remains pending an expedited DEA administrative hearing starting June 29 and ending no later than July 15, prompting state operators to file new DEA registration applications for manufacturing, distribution, and testing. Legal challenges to the order have emerged, while a May 12 Senate oversight hearing on DEA matters omitted rescheduling questions. Traders monitor hearing testimony and potential final rulemaking for full reform signals.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트$758,309 거래량
2026.03.31
6월 30일
2%
12월 31일
25%
$758,309 거래량
6월 30일
$336,932 거래량
2%
12월 31일
$156,494 거래량
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice under Acting Attorney General Todd Blanche issued a final DEA order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing federal protections and tax relief via Section 280E exemption for qualifying businesses. Broader rescheduling of botanical marijuana remains pending an expedited DEA administrative hearing starting June 29 and ending no later than July 15, prompting state operators to file new DEA registration applications for manufacturing, distribution, and testing. Legal challenges to the order have emerged, while a May 12 Senate oversight hearing on DEA matters omitted rescheduling questions. Traders monitor hearing testimony and potential final rulemaking for full reform signals.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
마켓 개설일: Feb 7, 2026, 5:04 PM ET
거래량
$758,309종료일
2026.03.31마켓 개설일
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.In late April 2026, the Department of Justice under Acting Attorney General Todd Blanche issued a final DEA order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing federal protections and tax relief via Section 280E exemption for qualifying businesses. Broader rescheduling of botanical marijuana remains pending an expedited DEA administrative hearing starting June 29 and ending no later than July 15, prompting state operators to file new DEA registration applications for manufacturing, distribution, and testing. Legal challenges to the order have emerged, while a May 12 Senate oversight hearing on DEA matters omitted rescheduling questions. Traders monitor hearing testimony and potential final rulemaking for full reform signals.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
거래량
$758,309종료일
2026.03.31마켓 개설일
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...In late April 2026, the Department of Justice under Acting Attorney General Todd Blanche issued a final DEA order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing federal protections and tax relief via Section 280E exemption for qualifying businesses. Broader rescheduling of botanical marijuana remains pending an expedited DEA administrative hearing starting June 29 and ending no later than July 15, prompting state operators to file new DEA registration applications for manufacturing, distribution, and testing. Legal challenges to the order have emerged, while a May 12 Senate oversight hearing on DEA matters omitted rescheduling questions. Traders monitor hearing testimony and potential final rulemaking for full reform signals.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문